Interests Include: Head and Neck Cancer, Skin Cancer, and Stereotactic Body Radiation Therapy
Dr. Ryan Lanning joined the faculty of the Department of Radiation Oncology in September 2016. He attended the University of California-Irvine on a Regents Scholarship, receiving a BS in Chemistry and Biology. He worked for a year in the Beckman Laser Institute and Medical Clinic as an optical engineer, where he played a key role in the development of diffuse optical tomography in solid tumors. He then completed an MD-PhD program at Harvard Medical School and MIT, where he performed graduate research in the Edwin L. Steele Laboratories under the tutelage of Dr. Rakesh Jain. His doctoral thesis was entitled “Tumor vasculature and microenvironment during progression and treatment: insights from optical microscopy”. He was the recipient of several awards during this period including a Whitaker Foundation Fellowship and a Department of Defense Pre-Doctoral Training Fellowship.
After an internship in Internal Medicine at the Brigham and Women’s Hospital in Boston, MA, Dr. Lanning completed a residency in Radiation Oncology at Memorial Sloan Kettering Cancer Center in New York, NY, where he continued his translational scientific work alongside his clinical training. He developed new targeted imaging and treatment agents for pancreatic cancer now progressing into clinical trials. He was also a clinical investigator on a clinical trial of selective radiation dose de-escalation in HPV-related head and neck cancer.
At the University, Dr. Lanning’s laboratory uses novel optical and molecular imaging to study the tumor microenvironment in response to radiation and targeted therapies in the preclinical setting and directly translating this work to personalizing cancer therapy in the clinic. By means of a technology dissemination grant, his lab will provide the Cancer Center with an entirely new modality of non-invasive, real-time tumor physiology and vessel architecture monitoring with broad applicability for studies across the spectrum of solid tumors.
Dr. Lanning’s clinical focus will be in the treatment of Head and Neck and Skin cancers.